日韩不卡Av一区二区三区,少妇高潮喷水在线观看

內(nèi)容概括

INTRODUCTION

Biopharmaceuticalindustry ofChinadeveloped behind the leading countries, however, it is growing dramaticallyfast during past decades. Chinese government invested in biopharmaceuticals, aswell as made the supporting policies. At present, biopharmaceutical industry isone of the leading industries inChina.

There were 36 listedbiopharmaceutical companies in 2015, the volume of sales reached RMB50.59billion, and the net profit obtained RMB9.24 billion.

Keep pace with thedevelopment of latest biopharmaceutical technologies, this industry dominatedthe whole pharmaceutical industry. Meanwhile, the awareness of health lifestyle of people has changed a lot, which focuses much more on preventionsinstead of therapy treatments. Those factors become incentives to the progressof biopharmaceutical enterprises.

1) TheAim of this report

n To provide readers with comprehensive & in-depthunderstanding ofChina’sbio-pharmaceutical industry;

n To understand the development situation ofbio-pharmaceutical industry inChina;

n Get more information of the major bio-pharmaceuticalproducers inChina;

n Gain insight into the major bio-pharmaceutical producersabout operation;

n To predict what future ofChinabio-pharmaceutical industrywill be;

n To reveal opportunities inChinabio-pharmaceutical industry.

2) Benefitfrom the report

n Financial performance in 2015 and YoY changes, includingrevenue, operating profit, net profit, revenue and gross profit margin frombio-pharmaceutical business;

n Changes of revenue and net profit in the latest five yearsand the reasons;

n Adjustment to business structure in the recent 2-3 years;

n Development strategy anddevelopment trends in the near future.

3) Deliverables

PDF-formatreport, with around 30-50 pages.

4) Timeneeded

Three working days needed.

報告目錄

Part	Contents
1	Executive summary
2	Ranking of main listed domestic bio-pharmaceutical enterprises in 2015
2.1	List ofChina’s listed bio-pharmaceutical enterprises
2.2	By revenue
2.3	By net profit
2.4	By total assets
2.5	By revenue and gross profit margin of bio-pharmaceutical business
2.6	By operating profit
2.7	By primary earnings per share
3	Analysis of listed bio-pharmaceutical enterprises
3.1	Jiangsu Sihuan Bioengineering Co., LTD
3.2	Hualan Biological Engineering, Inc.
3.3	Guilin Layn Natural Ingredients Corp.
3.4	Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
3.5	Jiangxi Boya Bio-pharmaceutical Co., Ltd.
3.6	Beijing Strong Biotechnologies, Inc.
3.7	Beijing Tiantan Biological Products Corporation Limited
3.8	China Animal Husbandry Industry Co., Ltd.
3.9	Shanghai Jiaoda Onlly Co.,Ltd.
3.10	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
3.11	Shanghai RAAS Blood Products Co., Ltd.
3.12	Beijing SL Pharmaceutical Co., Ltd.
3.13	Changchun High and New Technology Industry (Group) Inc.
3.14	Shenzhen Neptunus Bioengineering Co., Ltd.
3.15	Tonghua Dongbao Pharmaceutical Co., Ltd.
3.16	Changsheng Bio-technology Co., Ltd.
3.17	Sichuan Maccura Biotechnology Co., Ltd.
3.18	Zhongyuan Union Cell & Gene Engineering Grop., Ltd.
3.19	Shanghai Kehua Bioengineering Co., Ltd.
3.20	Staidson (Beijing) Biopharmaceuticals Co., Lt
3.21	Chongqing Zhifei Biological Products Co., Ltd.
3.22	Beijing Leadman Biochemistry Co., Ltd.
3.23	Ningbo Medicalsystem Biotechnology Co., Ltd.
3.24	Anhui Anke Biotechnology (Group) Co., Ltd.
3.25	Guangzhou Wondfo Biotech Co., Ltd.
3.26	Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
3.27	Da An Gene Co., Ltd. ofSunYat-senUniversity
3.28	Fujian Cosunter Pharmaceutical Co., Ltd.
3.29	Guangdong Vtr Bio-Tech Co., Ltd.
3.30	Zhong Zhu Holding Co., Ltd.
3.31	Zhenxing Biopharmaceutical and Chemical Co., Ltd.
3.32	Zhejiang Qianjiang Biochemical Co., Limited
3.33	Ginwa Enterprise (Group) Inc.
3.34	Shenzhen Cau Technology Co., Ltd.
3.35	Baotou Dongbao Bio-tech Co., Ltd.
3.36	Walvax Biotechnology Co., Ltd.

版權(quán)聲明

?本報告所有內(nèi)容受法律保護，中華人民共和國涉外調(diào)查許可證：國統(tǒng)涉外證字第1454號。本報告由中商產(chǎn)業(yè)研究院出品，報告版權(quán)歸中商產(chǎn)業(yè)研究院所有。本報告是中商產(chǎn)業(yè)研究院的研究與統(tǒng)計成果，報告為有償提供給購買報告的客戶內(nèi)部使用。未獲得中商產(chǎn)業(yè)研究院書面授權(quán)，任何網(wǎng)站或媒體不得轉(zhuǎn)載或引用，否則中商產(chǎn)業(yè)研究院有權(quán)依法追究其法律責任。如需訂閱研究報告，請直接聯(lián)系本網(wǎng)站，以便獲得全程優(yōu)質(zhì)完善服務(wù)。本報告目錄與內(nèi)容系中商產(chǎn)業(yè)研究院原創(chuàng)，未經(jīng)本公司事先書面許可，拒絕任何方式復(fù)制、轉(zhuǎn)載。在此，我們誠意向您推薦鑒別咨詢公司實力的主要方法。